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Abstract
Objective To explore and compare the diVerences in the
clinicopathological characteristics and prognosis of syn-
chronous primary endometrial and ovarian cancers with
primary endometrial cancer metastatic to adnexa.
Materials and methods Between January 1997 and Decem-
ber 2009, 51 cases with endometrial cancer simultaneously
with adnexa malignancy were identiWed. Among them,
there were 18 cases with synchronous primary cancers of
the endometrium and ovary (Group A) and 33 cases with
primary endometrial cancer metastatic to the adnexa
(Group B). Clinical and pathologic information was
obtained from medical records. Parametric methods were
used to compare clinical and pathologic features. Kaplan–
Meier survival analysis was performed and compared using
log-rank test.
Results The mean age at diagnosis of the disease was
56.6 § 10.8 years (range 34–76 years) in Group A and
53.1 § 9.5 years (range 37–76 years) in Group B. The two
groups’ distribution of preoperative image Wndings, size of
endometrial lesion, myometrial invasion, unilateral or bilat-
eral, cervix invasion, and postoperative radiation existed
signiWcant diVerences. With a mean follow-up time of
4.3 § 3.4 years (range 2–11 years), 5-year overall survival
(OS) was 75 and 56% in Groups A and B, respectively
(p = 0.034). The univariate analysis showed only postoper-
ative radiation and synchronous tumors were independent
factors which aVected OS (p = 0.015; p = 0.034) and pro-
gression-free survival (PFS) (p =0 . 0 1 5 ;   p = 0.036), respec-
tively. Not any feature was revealed by multivariate
analysis as independent prognostic factors.
Conclusion Our results showed that OS and PFS of syn-
chronous primary ovarian cancer in patients with endome-
trial cancer is better than those with ovarian metastasis
patients. Pre- and intra-operative, intensive and careful
assessment, and strict and continuous postoperative surveil-
lance should pay attention to the endometrial cancer
patients who preserved ovary for having possibility of
coexisting occult ovarian lesions.
Keywords Endometrial neoplasm · Adnexa neoplasm · 
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Introduction
It has been identiWed that primary cancer can occur in the
female reproductive organs simultaneously, especially with
endometrial and ovarian cancers. Endometrial and adnexa
malignancy may coexist in approximately 5% of all
patients with endometrial cancer and 10% of those with
ovarian cancer [1–4]. Patients with disease of both the
endometrium and the ovary can be classiWed into three
groups: (1) synchronous primary cancers of the endome-
trium and ovary, (2) endometrial cancer with metastasis to
the adnexa, and (3) ovarian cancer with metastasis to the
endometrial. Ulbright and Roth [5] proposed a set of histo-
logical criteria to distinguish the Wrst two groups in 1985.
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Then Scully et al. [1] described a similar but more exten-
sive list of clinical pathologic features used to diVerentiate
all the three groups. But there are still no absolute surgical
or histological criteria.
The aim of the present retrospective study was to assess
the clinical characteristics, pathologic patterns, and survival
experience of the 51 endometrial cancer patients simulta-
neously with adnexa malignancy.
Materials and methods
Between January 1997 and December 2009, the Depart-
ment of Gynecology Oncology of Zhejiang Provincial Can-
cer Hospital in China received and treated 818 patients with
primary endometrial cancer. Patients who received preoper-
ative radiation therapy or did not undergo surgery were
excluded. Patients’ medical history, pathologic reports, and
treatment records were collected. There were 51 cases of
primary endometrial cancer coexisting with adnexa malig-
nancies: among them, 18 cases are synchronous primary
cancers of the endometrium and ovary, and 33 cases are
endometrial cancer with metastasis to the adnexa. Clinical
information regarding age, preoperative image examination
and serum CA125 level, postoperative chemotherapy, and/
or radiation was gathered. Histologic and pathologic infor-
mation was collected, including tumor size, histological
type, pathologic grade, peritoneal Xuid cytology, invasive
depth of myometrium, uterine serosal involvement, lymph-
vascular space invasion (LVSI), cervical involvement, and
adnexa involvement.
All pathologic specimens were reviewed by our patholo-
gists according to the criteria described by Scully et al. The
pathologic criteria for synchronous primary cancers of the
endometrium and ovary were as follows: (1) histological
dissimilarity of tumors; (2) no or only superWcial myome-
trial invasion of endometrial tumor; (3) no vascular space
invasion of endometrial tumor; (4) atypical endometrial
hyperplasia additionally present; (5) absence of other evi-
dence of spread of endometrial tumor; (6) ovarian tumor
unilateral (80–90% of cases); (7) ovarian tumors located
mainly in parenchyma; (8) no vascular space invasion, sur-
face implants, or predominant hilar location in ovary; (9)
absence of other evidence of spread of ovarian tumor; and
(10) ovary endometriosis present.
Patients were divided into two groups according to the
histology of endometrial and ovarian. Group A meant
patients with synchronous endometrial and ovarian cancers.
Group B meant patients with endometrial cancers with
metastasis to adnexa. All patients’ stages were reviewed
and updated, based on the endometrial and ovarian cancer
staging criteria set by the International Federation of Gyne-
cology and Obstetrics (FIGO) [6].
Statistical analyses were performed using SPSS version
15.0 (SPSS Inc., Chicago, IL, USA). Pearson 2 or Fisher’s
exact test was carried out for analyzing the categorical vari-
ables with respect to the eVects of clinical and pathological
risk factors on the coexisting adnexa malignancy rate.
Associations between prognostic variables and survival
were compared using the log-rank and 2 tests, with a p
value <0.05 considered signiWcant. Multivariate analysis
was performed using Cox proportional hazards method. We
also analyzed follow-up results including progression-free
and overall survival (OS) of the two group patients, and
comprised survival curves performed using the Kaplan–
Meier method.
Results
The median age at diagnosis of the disease was
56.6 § 10.8 years (range 34–76 years) in Group A and
53.1 § 9.5 years (range 37–76 years) in Group B (p =
0.727). All patients underwent surgical staging with total or
radical abdominal hysterectomy (TH), bilateral salpingo-
oophorectomy (BSO), and selective or systemic bilateral
pelvic or/and para-aortic lymphadenectomy, according to
the NCCN Clinical Practice Guidelines in Oncology-Uter-
ine Neoplasms (2008). Patients with positive cervical
biopsy result or gross cervical involvement received radical
hysterectomy, BSO, cytology, and pelvic and para-aortic
lymph node dissection. TH/BSO, cytology, maximal debul-
king, omentectomy, and pelvic and para-aortic lymph node
dissection were carried out when patients had been found
intra-abdominal lesions including ascites, omentum, nodal,
and peritoneal disease. Before abdominal operation started,
each patient received peritoneal washing for cytological
examination. Pelvic and para-aortic lymph nodes were dis-
sected in 88.3 and 52.9% of patients, respectively. 29 cases
(56.9%) received omentum resection. The histology coinci-
dence rate of endometrium and ovary was 72.2%, while 5
cases (27.78%) had diVerent pathologic types in Group A,
including endometrioid carcinoma, papillary adenocarci-
noma, and serous papillary adenocarcinoma. In Group B,
12 cases (36.36%) were unilateral salpingo metastasis and 7
cases (21.21%) with bilateral salpingo metastasis. Thirty-
eight patients (74.5%) underwent postoperative therapy.
Among them, 8 (15.7%) had radiation alone; 24 (47.1%)
had chemotherapy alone; and 4 (7.8%) had both radiation
and chemotherapy after operation.
Table 1 showed the clinical and pathological features
and the diVerences of the constituent ratio of these two
groups. The distribution of features was similar between
two groups, including age, preoperative serum CA125
level, peritoneal washing, histology, grade, lymph-vascular
invasion, pelvic lymph nodes, and para-aortic lymph nodes.Arch Gynecol Obstet (2011) 283:1133–1137 1135
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But the two groups’ distribution of preoperative image Wnd-
ings, size of endometrial lesion, myometrial invasion, uni-
lateral or bilateral, cervix invasion, and postoperative
radiation existed signiWcant diVerences.
With a mean follow-up time of 4.3 § 3.4 years (range
2–11 years), 3- and 5-year OS was 82 and 75%, respectively,
in Group A. In Group B, 3- and 5-year OS was 65 and 56%,
respectively. The diVerence in OS between the two groups
was signiWcant (Z = 4.496,  p = 0.034; Fig. 1). Mean pro-
gression-free survival (PFS) was also signiWcantly longer
in Group A (3.9 § 3.2 years) compared to Group B
(2.8 § 2.1 years, Z = 6.552, p = 0.010; Fig. 2).
The log-rank univariate analysis of the two groups, only
postoperative radiation (2 = 5.873, p = 0.015; 2 = 5.887,
p = 0.015) and synchronous tumors (2 = 4.496, p = 0.034;
2 = 4.387, p = 0.036), showed that these two parameters
independently aVected OS and PFS. There was no feature
revealed by multivariate analysis (Cox regression) as an
independent prognostic factor.
Discussion
It has a low incidence of endometrial cancers coexisting
with adnexa tumors. Still there are no standard criteria for
diagnosis and treatment of this kind of patients. Synchro-
nous primary cancers of the endometrium and ovary occur
in approximately 10% of all women with ovarian cancer
and 5% of all women with endometrial cancer [7–9]. The
present study demonstrated that the overall rate of coexis-
ting adnexa malignance in endometrial cancer patients
was 6.23%. Among this, 2.20% patients were synchro-
nous primary cancers of endometrium and ovary, while
4.34% patients were endometrial cancer with adnexa
metastasis. It may be resulted from various human race
and diVerent area.
It had not found any signiWcant diVerence from the mean
age of these two groups. The common symptoms were lack
of speciality, and similar to endometrial or ovarian cancer
alone, including abnormal vaginal bleeding, ascites,
abdominal pain, pelvic mass, and abdominal bloating. The
early detection of ovarian cancer was likely due to early
symptom related to concurrent endometrial cancer [1].
Most of synchronous patients had clinical characteristics,
including young age, premenopausal, obesity, and nullipar-
ity. Patients with concordant endometrial tumors had a
favorable prognosis [2]. Similar results were obtained in
our study; synchronous cancer patients usually had earlier
stage, unilateral mass, smaller endometrial lesions, and
with more superWcial invasion to endometrium. Therefore,
these patients were easily detected and received early treat-
ment, and had better prognosis than those with metastasis
group. Chemotherapy was commonly used for Group A by
Table 1 Clinical and pathological characteristics
Variables Group A (%) 
(n = 18)
Group B (%) 
(n = 33)
p value
Mean age (years) 56.6 § 10.8 53.1 § 9.5 0.727
>45 14 (77.78) 27 (81.82)
·45 4 (22.22) 6 (18.18)
Serum CA125 (U/ml) 0.696
·35 2 (11.11) 6 (18.18)
>35 16 (88.89) 27 (81.82)
Preoperative image Wndings 0.042
Yes 11 (61.11) 10 (30.30)
No 7 (38.89) 23 (69.70)
Peritoneal cytology 1.000
Negative 15 (83.33) 27 (81.82)
Positive 3 (16.67) 6 (18.18)
Size of endometrial lesion 0.013
·2 cm 16 (88.89) 17 (51.52)
>2 cm 2 (11.11) 16 (48.48)
Endometrial histology 0.732
Endometrioid type 13 (72.22) 26 (78.79)
Non-endometrioid type 5 (27.78) 7 (21.21)
Endometrial tumor grade 0.055
1 9 (50.00) 7 (21.21)
2 6 (33.33) 11 (33.33)
3 3 (16.67) 15 (45.46)
Myometrial invasion 0.002
Limited to endometrium 5 (27.78) 1 (3.03)
<1/2 11 (61.11) 14 (42.42)
¸1/2 2 (11.11) 18 (54.55)
Ovary malignancy involvement 0.015
Unilateral 13 (72.22) 13 (39.39)
Bilateral 5 (27.78) 9 (27.27)
Cervix invasion 0.004
No 15 (83.33) 12 (36.36)
Yes 3 (16.67) 21 (63.64)
LVSI 0.134
No 17 (94.44) 25 (75.76)
Yes 1 (5.56) 8 (24.24)
Pelvic lymph nodes 0.136
Negative 11 (61.11) 22 (66.67)
Positive 1 (5.56) 11 (33.33)
Not available 6 (33.33) 0
Para-aortic lymph nodes 0.631
Negative 4 (22.22) 12 (36.36)
Positive 1 (5.56) 7 (21.21)
Not available 13 (72.22) 14 (42.42)
Postoperative radiation 0.004
No 18 (100) 21 (63.64)
Yes 0 (0) 12 (36.36)
Postoperative chemotherapy 0.003
No 3 (16.67) 20 (60.61)
Yes 15 (83.33) 13 (39.39)1136 Arch Gynecol Obstet (2011) 283:1133–1137
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most of the doctors due to two sites of lesion. This retro-
spective study cannot further assess the role of chemother-
apy and radiation because of the variety of adjuvant
regiment administered. Up to now, there is no standard
method to the postoperative adjuvant therapies for patients
with synchronous endometrial and ovarian cancers.
Because of small number of cases, the inXuence of the post-
operative adjuvant therapy needs to be further investigated.
The GOG study found that 74 patients with simulta-
neously detected endometrial and ovarian cancers had an
overall good prognosis with a 5-year survival of 85.9% and
10-year survival of 80.3% [3]. In our cohort, it was obvious
that the survival rate of Group A was better than that of
Group B. We found that patients with synchronous primary
cancers had a better survival than those with metastasis.
This result was similar to data reported in the literature [2,
7]. Prognostic correlation factors of synchronous endome-
trial and ovarian cancers, including grade, early stage, and
deep myometrial invasion [10,  11], are frequently seen.
Univariate analysis conWrmed that synchronous tumors and
postoperative radiation were two independent prognostic
factors of survival. But there was no statistically signiWcant
diVerence in prognosis by multivariate analysis (Cox
regression).
The incidence of ovarian metastasis in women with clin-
ical stage I endometrial cancer has been reported, by most
studies, to be approximately 5%. This rate of ovarian
metastasis has provided the basis for practice of removing
both ovaries at the time of surgery, even in young patients.
Gemer et al. [12] reported that the ovarian metastasis is
microscopic in 18–70% of the endometrial carcinoma. Pre-
operative imaging studies or macroscopic intra-operative
appearance cannot be relied on to exclude their presence
[12]. Our data also showed that ovary metastasis of endo-
metrial cancer was not easy to be detected by preoperative
imaging detections.
It should be noted that ten cases (19.61%) were aged less
than 45 years when they were diagnosed in our study.
Walsh et al. [4] reported among 102 young women who
underwent hysterectomy for endometrial cancer: 26 (25%)
were found to have coexisting epithelial ovarian tumors, 23
were classiWed as synchronous primaries, and 3 as metasta-
sis. Careful pre- and intra-operative assessment of adnexa is
mandatory in young women with endometrial cancer [4].
However, Wright et al. [13] reported that ovarian preserva-
tion in premenopausal women with early-stage endometrial
cancer might be safe and not associated with an increase in
cancer-related mortality. Despite the potential for occult
ovarian tumors in women undergoing ovarian preservation,
survival was not compromised in their series. The risk
should be taken into consideration when preserving the
ovary in the treatment for young patients [14–18]. Macro-
scopic appearance of the ovary should not be relied on as an
only basis. Kotera et al. [19] reported that it was valuable
and feasible for early stage (stage IA) epithelial ovarian
cancer patient who underwent opposite ovary wedge resec-
tion. One can check whether it exists opposite ovary metas-
tases through frozen section; on the other hand, it can
preserve endocrine function. Therefore, careful intra-opera-
tive evaluation, wedge-shaped resection of ovary and fro-
zen section seems necessary before preserving the ovary.
Careful oncologic, psychotherapeutic, genetic, and repro-
ductive counseling is advised before oVering a non-standard
treatment strategy to young endometrial cancer patients.
Fig. 1 Kaplan–Meier chart for overall survival (OS). Survival curve
showed that OS of Group A was superior to that of Group B. “Censored”
means cases without endpoint event at the end of follow-up
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Fig. 2 Kaplan–Meier chart for progression-free survival (PFS). PFS
curve showed that PFS of Group A was superior to that of Group B.
“Censored” means cases without endpoint event at the end of
follow-up
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Long-term risks and beneWts of ovarian preservation should
be forward discussed [20]. The pathologists and clinical
oncologists should pay more attention to the problem of
making diagnosis and individual treatment [21].
Patients with synchronous ovarian and endometrial can-
cers may represent cases of a single primary tumor with
metastasis (SPM) or dual primary tumors (DP). Ramus
et al. [22] showed that genetic analysis may represent a
powerful tool for use in clinical practice for distinguishing
between SPM and DP in patients with synchronous ovar-
ian/endometrial cancer and predicting disease outcome.
The data also suggested a hitherto uncharacterized level of
heterogeneity in these cases, which, if accurately deWned,
could lead to improved treatment and survival. In the
future, this might lead to improved clinical management
and outcome for the disease.
Conclusion
Our results agree with recent reports which found patho-
logic feature and outcome of patients with synchronous
endometrial and ovarian cancers. Synchronous cancer
patients usually have early stage, unilateral mass, small
endometrial lesions, and with more superWcial invasion to
endometrium. Despite the retrospective design and limited
cases of this study, our results suggest that endometrial can-
cer patients with synchronous primary cancer have a better
survival than those with ovarian metastasis group. Intensive
and careful assessment is required despite the incidence of
the occult ovarian lesion with young endometrial cancer
patients is uncommon. Endometrial patients who preserved
ovary need to have strict and continued postoperative sur-
veillance to the retained adnexa.
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